Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM). A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA). We describe a case of biopsy-proven renal thrombotic microangiopathy associated with the use o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Keer, Jan, Delforge, Michel, Dierickx, Daan, Peerlinck, Kathelijne, Lerut, Evelyne, Sprangers, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884801/
https://www.ncbi.nlm.nih.gov/pubmed/27293920
http://dx.doi.org/10.1155/2016/6020691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884801/
https://www.ncbi.nlm.nih.gov/pubmed/27293920
http://dx.doi.org/10.1155/2016/6020691

Ejemplares similares